SG10201701037WA - Factor viii complex with xten and von willebrand factor protein, and uses thereof - Google Patents

Factor viii complex with xten and von willebrand factor protein, and uses thereof

Info

Publication number
SG10201701037WA
SG10201701037WA SG10201701037WA SG10201701037WA SG10201701037WA SG 10201701037W A SG10201701037W A SG 10201701037WA SG 10201701037W A SG10201701037W A SG 10201701037WA SG 10201701037W A SG10201701037W A SG 10201701037WA SG 10201701037W A SG10201701037W A SG 10201701037WA
Authority
SG
Singapore
Prior art keywords
xten
von willebrand
viii complex
factor
protein
Prior art date
Application number
SG10201701037WA
Inventor
Ekta Seth Chhabra
Tongyao Liu
Pei-Yun Chang
Robert T Peters
John Kulman
Original Assignee
Amunix Operating Inc
Biogen Ma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amunix Operating Inc, Biogen Ma Inc filed Critical Amunix Operating Inc
Publication of SG10201701037WA publication Critical patent/SG10201701037WA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
SG10201701037WA 2012-07-11 2013-07-10 Factor viii complex with xten and von willebrand factor protein, and uses thereof SG10201701037WA (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201261670401P 2012-07-11 2012-07-11
US201361759819P 2013-02-01 2013-02-01
US201361801504P 2013-03-15 2013-03-15
US201361801544P 2013-03-15 2013-03-15
US201361827158P 2013-05-24 2013-05-24
US201361840811P 2013-06-28 2013-06-28

Publications (1)

Publication Number Publication Date
SG10201701037WA true SG10201701037WA (en) 2017-03-30

Family

ID=49916682

Family Applications (3)

Application Number Title Priority Date Filing Date
SG11201500045RA SG11201500045RA (en) 2012-07-11 2013-07-10 Factor viii complex with xten and von willebrand factor protein, and uses thereof
SG10201701037WA SG10201701037WA (en) 2012-07-11 2013-07-10 Factor viii complex with xten and von willebrand factor protein, and uses thereof
SG10201913893XA SG10201913893XA (en) 2012-07-11 2013-07-10 Factor viii complex with xten and von willebrand factor protein, and uses thereof

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201500045RA SG11201500045RA (en) 2012-07-11 2013-07-10 Factor viii complex with xten and von willebrand factor protein, and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201913893XA SG10201913893XA (en) 2012-07-11 2013-07-10 Factor viii complex with xten and von willebrand factor protein, and uses thereof

Country Status (31)

Country Link
US (3) US10138291B2 (en)
EP (3) EP2882450B1 (en)
JP (5) JP6603128B2 (en)
KR (2) KR102329315B1 (en)
CN (2) CN104661674A (en)
AR (1) AR091735A1 (en)
AU (4) AU2013290173B2 (en)
BR (1) BR112015000267B1 (en)
CA (1) CA2878679A1 (en)
CL (1) CL2015000060A1 (en)
CO (1) CO7170123A2 (en)
CY (1) CY1122729T1 (en)
DK (1) DK2882450T3 (en)
EA (2) EA201792485A3 (en)
ES (1) ES2770501T3 (en)
HK (1) HK1211228A1 (en)
HR (1) HRP20200007T1 (en)
HU (1) HUE047088T2 (en)
IL (1) IL236412B (en)
LT (1) LT2882450T (en)
MX (1) MX2015000397A (en)
NZ (1) NZ703366A (en)
PH (1) PH12015500039A1 (en)
PL (1) PL2882450T3 (en)
PT (1) PT2882450T (en)
RS (1) RS59876B1 (en)
SG (3) SG11201500045RA (en)
SI (1) SI2882450T1 (en)
TW (1) TWI667258B (en)
UA (1) UA116632C2 (en)
WO (1) WO2014011819A2 (en)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ628987A (en) * 2009-02-03 2015-11-27 Amunix Operating Inc Extended recombinant polypeptides and compositions comprising same
US8716448B2 (en) 2009-02-03 2014-05-06 Amunix Operating Inc. Coagulation factor VII compositions and methods of making and using same
NZ626945A (en) 2012-01-12 2016-10-28 Biogen Ma Inc Chimeric factor viii polypeptides and uses thereof
KR20190094480A (en) 2012-02-15 2019-08-13 바이오버라티브 테라퓨틱스 인크. Recombinant factor viii proteins
PT3564260T (en) 2012-02-15 2023-01-18 Bioverativ Therapeutics Inc Factor viii compositions and methods of making and using same
EP2870250B2 (en) 2012-07-06 2022-06-29 Bioverativ Therapeutics Inc. Cell line expressing single chain factor viii polypeptides and uses thereof
SG11201500045RA (en) 2012-07-11 2015-02-27 Amunix Operating Inc Factor viii complex with xten and von willebrand factor protein, and uses thereof
DK2956477T4 (en) 2013-02-15 2024-04-15 Bioverativ Therapeutics Inc OPTIMIZED FACTOR VIII GENE
TWI745671B (en) 2013-03-15 2021-11-11 美商百歐維拉提夫治療公司 Factor ix polypeptide formulations
DK2796145T3 (en) * 2013-04-22 2018-01-29 Csl Ltd A covalent complex of von Willebrand factor and factor VIII linked by a disulfide bridge
CN113831415A (en) * 2013-06-28 2021-12-24 比奥贝拉蒂治疗公司 Thrombin cleavable linker with XTEN and uses thereof
TWI667255B (en) 2013-08-14 2019-08-01 美商生物化學醫療公司 Factor viii-xten fusions and uses thereof
BR122023020301A2 (en) * 2014-01-10 2023-12-12 Bioverativ Therapeutics Inc. USE OF A CHIMERICAL PROTEIN COMPRISING AN FVIII PROTEIN
AU2016231328B2 (en) * 2015-03-06 2018-07-05 CSL Behring Lengnau AG Compounds for improving the half-life of von Willebrand factor
RU2017145014A (en) * 2015-05-22 2019-06-24 Цсл Беринг Ленгнау Аг DIFFERENT POLYPEPTIDES OF THE VILLEBRAND VON FACTOR FOR THE TREATMENT OF HEMOPHILIA
WO2017024060A1 (en) * 2015-08-03 2017-02-09 Biogen Ma Inc. Factor ix fusion proteins and methods of making and using same
AU2016304842A1 (en) 2015-08-12 2018-02-22 Cell Machines, Inc. Methods and compositions related to long half-life coagulation complexes
US11713358B2 (en) * 2015-08-28 2023-08-01 Amunix Pharmaceuticals, Inc. Chimeric polypeptide assembly and methods of making and using the same
WO2017117631A1 (en) 2016-01-07 2017-07-13 Csl Limited Mutated truncated von willebrand factor
US11753461B2 (en) 2016-02-01 2023-09-12 Bioverativ Therapeutics Inc. Optimized factor VIII genes
WO2017198435A1 (en) 2016-05-20 2017-11-23 Octapharma Ag Glycosylated vwf fusion proteins with improved pharmacokinetics
US11046749B2 (en) 2016-06-24 2021-06-29 Mogam Institute For Biomedical Research Chimera protein comprising FVIII and vWF factors, and use thereof
CN106279437B (en) * 2016-08-19 2017-10-31 安源医药科技（上海）有限公司 Hyperglycosylated human coagulation factor VIII fusion proteins and preparation method thereof and purposes
CN107759694B (en) 2016-08-19 2023-01-13 安源医药科技（上海）有限公司 Bispecific antibody, preparation method and application thereof
US10738338B2 (en) 2016-10-18 2020-08-11 The Research Foundation for the State University Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
CN110381986B (en) 2016-11-11 2023-08-18 康诺贝林伦瑙有限公司 Truncated von willebrand factor polypeptides for extravascular administration to treat or prevent coagulation disorders
JP7252890B2 (en) 2016-11-11 2023-04-05 ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト Truncated von Willebrand factor polypeptides for treating hemophilia
CN110520149A (en) 2016-12-02 2019-11-29 比奥维拉迪维治疗股份有限公司 Induce the method to the immunological tolerance of coagulation factor
MX2019006444A (en) 2016-12-02 2019-10-30 Bioverativ Therapeutics Inc Methods of treating hemophilic arthropathy using chimeric clotting factors.
CA3051862A1 (en) 2017-01-31 2018-08-09 Bioverativ Therapeutics Inc. Factor ix fusion proteins and methods of making and using same
GB201707139D0 (en) * 2017-05-04 2017-06-21 Imp Innovations Ltd Polypeptides
CA3072334A1 (en) 2017-08-09 2019-02-14 Bioverativ Therapeutics Inc. Nucleic acid molecules and uses thereof
US20200385469A1 (en) * 2017-12-21 2020-12-10 Amunix Pharmaceuticals, Inc. Release segments and binding compositions comprising same
BR112020022164A2 (en) * 2018-05-18 2021-02-02 Bioverativ Therapeutics Inc. methods of treating hemophilia a
AU2019319984A1 (en) 2018-08-09 2021-03-04 Bioverativ Therapeutics Inc. Nucleic acid molecules and uses thereof for non-viral gene therapy
WO2020102741A1 (en) 2018-11-15 2020-05-22 Quantum-Si Incorporated Methods and compositions for protein sequencing
CA3121786A1 (en) 2018-12-06 2020-06-11 Bioverativ Therapeutics Inc. Use of lentiviral vectors expressing factor ix
US10654911B1 (en) * 2019-04-02 2020-05-19 Beijing Neoletix Biological Technology Co., Ltd. Vector co-expressing truncated von Willebrand factor and factor VIII
CA3144630A1 (en) * 2019-06-19 2020-12-24 Bioverativ Therapeutics Inc. Methods and compositions for treating hemophilia and low bone mineral density
CN112175088B (en) * 2019-07-02 2023-03-28 江苏晟斯生物制药有限公司 FIX fusion proteins, conjugates and uses thereof
WO2021043127A1 (en) * 2019-09-02 2021-03-11 甘李药业股份有限公司 Chimeric protein
MX2022005676A (en) 2019-11-13 2022-10-27 Amunix Pharmaceuticals Inc Barcoded xten polypeptides and compositions thereof, and methods for making and using the same.
EP4085077A4 (en) 2019-12-31 2024-01-17 Beijing Ql Biopharmaceutical Co Ltd Fusion proteins of glp-1 and gdf15 and conjugates thereof
CN113728013B (en) 2020-01-11 2022-06-14 北京质肽生物医药科技有限公司 Conjugates of fusion proteins of GLP-1 and FGF21
KR20230012052A (en) * 2020-05-20 2023-01-25 퀀텀-에스아이 인코포레이티드 Methods and compositions for protein sequencing
CN115925995A (en) 2020-09-30 2023-04-07 北京质肽生物医药科技有限公司 Polypeptide Conjugates and Methods of Use
EP4358938A1 (en) 2021-06-23 2024-05-01 Bioverativ Therapeutics Inc. Formulations of factor viii chimeric proteins and uses thereof
CN113862301A (en) * 2021-08-25 2021-12-31 上海交通大学医学院附属瑞金医院 VWF propeptide expression vector and preparation method and application thereof

Family Cites Families (144)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4215051A (en) 1979-08-29 1980-07-29 Standard Oil Company (Indiana) Formation, purification and recovery of phthalic anhydride
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US5981216A (en) 1985-04-01 1999-11-09 Alusuisse Holdings A.G. Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
WO1986006101A1 (en) 1985-04-12 1986-10-23 Genetics Institute, Inc. Novel procoagulant proteins
KR910006424B1 (en) 1985-08-21 1991-08-24 인코텍스 비.브이 Method of manufacturing knitted briefs
EP0253870B1 (en) 1986-01-03 1993-03-31 Genetics Institute, Inc. Method for producing factor viii:c-type proteins
US5595886A (en) 1986-01-27 1997-01-21 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US5610278A (en) 1986-06-24 1997-03-11 Novo Nordisk A/S Process for producing a coagulation active complex of factor VIII fragments
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
DE3883899T3 (en) 1987-03-18 1999-04-22 Sb2 Inc CHANGED ANTIBODIES.
CA1331157C (en) 1987-04-06 1994-08-02 Randal J. Kaufman Method for producing factor viii:c-type proteins
US6060447A (en) 1987-05-19 2000-05-09 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
US6346513B1 (en) 1987-06-12 2002-02-12 Baxter Trading Gmbh Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
IE69026B1 (en) 1987-06-12 1996-08-07 Immuno Ag Novel proteins with factor VIII activity process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
DE3720246A1 (en) 1987-06-19 1988-12-29 Behringwerke Ag FACTOR VIII: C-LIKE MOLECULE WITH COAGULATION ACTIVITY
FR2619314B1 (en) 1987-08-11 1990-06-15 Transgene Sa FACTOR VIII ANALOG, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME
US4994371A (en) 1987-08-28 1991-02-19 Davie Earl W DNA preparation of Christmas factor and use of DNA sequences
US6780613B1 (en) 1988-10-28 2004-08-24 Genentech, Inc. Growth hormone variants
US5004803A (en) 1988-11-14 1991-04-02 Genetics Institute, Inc. Production of procoagulant proteins
SE465222C5 (en) 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab A recombinant human factor VIII derivative and process for its preparation
US5846951A (en) 1991-06-06 1998-12-08 The School Of Pharmacy, University Of London Pharmaceutical compositions
MX9204374A (en) 1991-07-25 1993-03-01 Idec Pharma Corp RECOMBINANT ANTIBODY AND METHOD FOR ITS PRODUCTION.
US5859204A (en) 1992-04-07 1999-01-12 Emory University Modified factor VIII
US5364771A (en) 1992-04-07 1994-11-15 Emory University Hybrid human/porcine factor VIII
US6376463B1 (en) 1992-04-07 2002-04-23 Emory University Modified factor VIII
US6037452A (en) 1992-04-10 2000-03-14 Alpha Therapeutic Corporation Poly(alkylene oxide)-Factor VIII or Factor IX conjugate
US5563045A (en) 1992-11-13 1996-10-08 Genetics Institute, Inc. Chimeric procoagulant proteins
SE504074C2 (en) 1993-07-05 1996-11-04 Pharmacia Ab Protein preparation for subcutaneous, intramuscular or intradermal administration
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
GB9422383D0 (en) 1994-11-05 1995-01-04 Wellcome Found Antibodies
US6818439B1 (en) 1994-12-30 2004-11-16 Chiron Corporation Methods for administration of recombinant gene delivery vehicles for treatment of hemophilia and other disorders
US6030613A (en) 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US6485726B1 (en) 1995-01-17 2002-11-26 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US6086875A (en) 1995-01-17 2000-07-11 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
SE9503380D0 (en) 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
US6458563B1 (en) 1996-06-26 2002-10-01 Emory University Modified factor VIII
CA2262405A1 (en) 1996-08-02 1998-02-12 Bristol-Myers Squibb Company A method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
CA2225189C (en) 1997-03-06 2010-05-25 Queen's University At Kingston Canine factor viii gene, protein and methods of use
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6242195B1 (en) 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
JP2002510481A (en) 1998-04-02 2002-04-09 ジェネンテック・インコーポレーテッド Antibody variants and fragments thereof
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
WO2000009560A2 (en) 1998-08-17 2000-02-24 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
EP1006183A1 (en) 1998-12-03 2000-06-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Recombinant soluble Fc receptors
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
PL209786B1 (en) 1999-01-15 2011-10-31 Genentech Inc Variant of mother polypeptide containing Fc region, polypeptide containing variant of Fc region with altered affinity of Fc gamma receptor binding (Fc R), polypeptide containing variant of Fc region with altered affinity of Fc gamma neonatal receptor binding (Fc Rn), composition, isolated nucleic acid, vector, host cell, method for obtaining polypeptide variant, the use thereof and method for obtaining region Fc variant
US7829085B2 (en) 1999-07-14 2010-11-09 Life Sciences Research Partners Vzw Methods of treating hemostasis disorders using antibodies binding the C1 domain of factor VIII
WO2001079442A2 (en) 2000-04-12 2001-10-25 Human Genome Sciences, Inc. Albumin fusion proteins
JP2003533537A (en) 2000-05-16 2003-11-11 リポクセン テクノロジーズ リミテッド Derivatization of proteins
GB0029407D0 (en) 2000-12-01 2001-01-17 Affitech As Product
ES2649037T3 (en) 2000-12-12 2018-01-09 Medimmune, Llc Molecules with prolonged half-lives, compositions and uses thereof
WO2002076489A1 (en) 2001-03-09 2002-10-03 Dyax Corp. Serum albumin binding moieties
KR101271635B1 (en) 2001-12-21 2013-06-12 휴먼 게놈 사이언시즈, 인코포레이티드 Albumin fusion proteins
ES2500918T3 (en) 2001-12-21 2014-10-01 Human Genome Sciences, Inc. Albumin and interferon beta fusion proteins
US20080194481A1 (en) 2001-12-21 2008-08-14 Human Genome Sciences, Inc. Albumin Fusion Proteins
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US20040018557A1 (en) 2002-03-01 2004-01-29 Immunomedics, Inc. Bispecific antibody point mutations for enhancing rate of clearance
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
AU2002316574B2 (en) 2002-03-15 2008-05-01 Brandeis University Central airway administration for systemic delivery of therapeutics
ATE536188T1 (en) 2002-08-14 2011-12-15 Macrogenics Inc FCGAMMARIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
WO2004027901A2 (en) 2002-09-17 2004-04-01 Diffusion Science, Inc. Electrochemical generation, storage and reaction of hydrogen and oxygen using gas permeable catalyst-coated hollow microspheres
ATE541857T1 (en) 2002-09-27 2012-02-15 Xencor Inc OPTIMIZED FC VARIANTS AND MANUFACTURING PROCESSES THEREOF
JP4768439B2 (en) 2002-10-15 2011-09-07 アボット バイオセラピューティクス コーポレイション Modification of antibody FcRn binding affinity or serum half-life by mutagenesis
GB2395337B (en) 2002-11-14 2005-12-28 Gary Michael Wilson Warning Unit
JP2006524039A (en) 2003-01-09 2006-10-26 マクロジェニクス，インコーポレーテッド Identification and production of antibody containing mutant Fc region and use thereof
US7041635B2 (en) 2003-01-28 2006-05-09 In2Gen Co., Ltd. Factor VIII polypeptide
KR101085375B1 (en) 2003-02-26 2011-11-21 넥타르 테라퓨틱스 Polymer-factor ? moiety conjugates
US7632895B2 (en) 2003-02-28 2009-12-15 Kuraray Co., Ltd. Curable resin composition
US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US7348004B2 (en) 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
DE602004031390D1 (en) 2003-05-06 2011-03-24 Syntonix Pharmaceuticals Inc Coagulation factor VII-Fc chimeric proteins for the treatment of hemostatic diseases
JP4566194B2 (en) 2003-08-12 2010-10-20 リポクセン テクノロジーズ リミテッド Sialic acid derivatives for protein derivatization and conjugation
GB0324368D0 (en) 2003-10-17 2003-11-19 Univ Cambridge Tech Polypeptides including modified constant regions
US7211559B2 (en) 2003-10-31 2007-05-01 University Of Maryland, Baltimore Factor VIII compositions and methods
WO2005047327A2 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
US20050249723A1 (en) 2003-12-22 2005-11-10 Xencor, Inc. Fc polypeptides with novel Fc ligand binding sites
BRPI0506771A (en) 2004-01-12 2007-05-22 Applied Molecular Evolution antibody and pharmaceutical composition
AU2005227326B2 (en) 2004-03-24 2009-12-03 Xencor, Inc. Immunoglobulin variants outside the Fc region
WO2005123780A2 (en) 2004-04-09 2005-12-29 Protein Design Labs, Inc. Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
WO2006085967A2 (en) 2004-07-09 2006-08-17 Xencor, Inc. OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS
EP3342782B1 (en) 2004-07-15 2022-08-17 Xencor, Inc. Optimized fc variants
US7566701B2 (en) 2004-09-07 2009-07-28 Archemix Corp. Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics
WO2006047350A2 (en) 2004-10-21 2006-05-04 Xencor, Inc. IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION
WO2006071801A2 (en) * 2004-12-27 2006-07-06 Baxter International Inc Polymer-von willebrand factor-conjugates
WO2007021494A2 (en) 2005-08-12 2007-02-22 Human Genome Sciences, Inc. Albumin fusion proteins
EP1996220B2 (en) 2006-03-06 2023-08-16 Amunix Operating Inc. Unstructured recombinant polymers and uses thereof
US7846445B2 (en) * 2005-09-27 2010-12-07 Amunix Operating, Inc. Methods for production of unstructured recombinant polymers and uses thereof
JP5800458B2 (en) 2006-06-14 2015-10-28 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー Fusion protein cleavable by proteolysis with blood clotting factor
WO2008011633A2 (en) 2006-07-21 2008-01-24 Neose Technologies, Inc. Glycosylation of peptides via o-linked glycosylation sequences
US20100254944A1 (en) 2006-09-14 2010-10-07 Mani Subramanian Albumin Fusion Proteins
US20100075375A1 (en) 2006-10-03 2010-03-25 Novo Nordisk A/S Methods for the purification of polypeptide conjugates
EP2068907B1 (en) 2006-10-04 2017-11-29 Novo Nordisk A/S Glycerol linked pegylated sugars and glycopeptides
JP5448839B2 (en) * 2006-12-22 2014-03-19 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー Modified clotting factor with long half-life in vivo
EP1935430A1 (en) 2006-12-22 2008-06-25 CSL Behring GmbH Modified coagulation factors with prolonged in vivo half-life
DK2173890T3 (en) 2007-06-21 2011-06-27 Univ Muenchen Tech Biologically active proteins with increased stability in vivo and / or in vitro
EP2185701A4 (en) 2007-08-15 2011-03-02 Amunix Operating Inc Compositions and methods for modifying properties of biologically active polypeptides
WO2009058446A1 (en) 2007-11-01 2009-05-07 University Of Rochester Recombinant factor viii having increased stability
KR20100095441A (en) 2007-11-09 2010-08-30 백스터 인터내셔널 인코포레이티드 Modified recombinant factor viii and von willebrand factor and methods of use
CN101952016A (en) 2007-12-28 2011-01-19 巴克斯特国际公司 Reorganization VWF prescription
ES2531464T3 (en) * 2008-06-24 2015-03-16 Csl Behring Gmbh Factor VIII, von Willebrand factor or its complexes with prolonged in vivo half-life
CA2744340A1 (en) 2008-11-24 2010-05-27 Bayer Healthcare Llc Method of determining pegylated blood coagulation factor activity in a silica-based activated partial thromboplastin time assay
US8716448B2 (en) 2009-02-03 2014-05-06 Amunix Operating Inc. Coagulation factor VII compositions and methods of making and using same
NZ628987A (en) 2009-02-03 2015-11-27 Amunix Operating Inc Extended recombinant polypeptides and compositions comprising same
US8703717B2 (en) 2009-02-03 2014-04-22 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
US8680050B2 (en) 2009-02-03 2014-03-25 Amunix Operating Inc. Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
EP3061460A1 (en) 2009-04-10 2016-08-31 Tufts Medical Center, Inc. Par-1 activation by metalloproteinase-1 (mmp-1)
CN102481331B (en) 2009-06-08 2017-09-22 阿穆尼克斯运营公司 Glucose adjusts polypeptide and its preparation and application
NZ621868A (en) 2009-06-08 2015-10-30 Amunix Operating Inc Growth hormone polypeptides and methods of making and using same
KR20120061898A (en) 2009-08-20 2012-06-13 체에스엘 베링 게엠베하 Albumin fused coagulation factors for non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders
WO2011028344A2 (en) 2009-08-25 2011-03-10 Amunix Operating Inc. Interleukin-1 receptor antagonist compositions and methods of making and using same
AU2010319425B2 (en) * 2009-11-13 2015-07-02 Grifols Therapeutics Inc. Von Willebrand factor (vWF)-containing preparations, and methods, kits, and uses related thereto
US9050318B2 (en) * 2009-12-06 2015-06-09 Biogen Idec Hemophilia Inc. Factor VIII-Fc chimeric and hybrid polypeptides, and methods of use thereof
EP2536753B1 (en) * 2010-02-16 2017-12-20 Novo Nordisk A/S Factor viii molecules with reduced vwf binding
EP2977055A1 (en) 2010-02-16 2016-01-27 Novo Nordisk A/S Factor viii fusion protein
CA2799969C (en) 2010-05-20 2019-06-25 Allergan, Inc. Degradable clostridial toxins
AU2011274423B2 (en) 2010-07-09 2016-02-11 Bioverativ Therapeutics Inc. Chimeric clotting factors
WO2012006623A1 (en) 2010-07-09 2012-01-12 Biogen Idec Hemophilia Inc. Systems for factor viii processing and methods thereof
US20130017997A1 (en) 2010-08-19 2013-01-17 Amunix Operating Inc. Factor VIII Compositions and Methods of Making and Using Same
NZ626945A (en) * 2012-01-12 2016-10-28 Biogen Ma Inc Chimeric factor viii polypeptides and uses thereof
PT3564260T (en) 2012-02-15 2023-01-18 Bioverativ Therapeutics Inc Factor viii compositions and methods of making and using same
KR20190094480A (en) 2012-02-15 2019-08-13 바이오버라티브 테라퓨틱스 인크. Recombinant factor viii proteins
SG11201500045RA (en) 2012-07-11 2015-02-27 Amunix Operating Inc Factor viii complex with xten and von willebrand factor protein, and uses thereof
CN113831415A (en) 2013-06-28 2021-12-24 比奥贝拉蒂治疗公司 Thrombin cleavable linker with XTEN and uses thereof
WO2014210547A1 (en) 2013-06-28 2014-12-31 Biogen Idec Ma Inc. Thrombin cleavable linker
BR122023020301A2 (en) 2014-01-10 2023-12-12 Bioverativ Therapeutics Inc. USE OF A CHIMERICAL PROTEIN COMPRISING AN FVIII PROTEIN
BR112020022164A2 (en) * 2018-05-18 2021-02-02 Bioverativ Therapeutics Inc. methods of treating hemophilia a

Also Published As

Publication number Publication date
JP2018102323A (en) 2018-07-05
JP7022165B2 (en) 2022-02-17
EP4269431A1 (en) 2023-11-01
CL2015000060A1 (en) 2015-08-28
JP2022000471A (en) 2022-01-04
HRP20200007T1 (en) 2020-03-20
AU2020264355A1 (en) 2020-12-03
IL236412B (en) 2020-10-29
UA116632C2 (en) 2018-04-25
TW201414749A (en) 2014-04-16
PL2882450T3 (en) 2020-06-29
EP2882450A4 (en) 2016-06-22
EA201792485A2 (en) 2018-08-31
BR112015000267B1 (en) 2023-01-24
JP6603128B2 (en) 2019-11-06
DK2882450T3 (en) 2020-02-24
WO2014011819A2 (en) 2014-01-16
IL236412A0 (en) 2015-02-26
US20150266943A1 (en) 2015-09-24
CN104661674A (en) 2015-05-27
EP3674410A1 (en) 2020-07-01
JP2023166024A (en) 2023-11-17
RS59876B1 (en) 2020-03-31
HUE047088T2 (en) 2020-04-28
EP2882450B1 (en) 2019-11-27
KR20210143931A (en) 2021-11-29
KR20150036510A (en) 2015-04-07
JP2020078352A (en) 2020-05-28
CN110054699A (en) 2019-07-26
CA2878679A1 (en) 2014-01-16
BR112015000267A2 (en) 2018-03-06
JP2015527882A (en) 2015-09-24
US11091534B2 (en) 2021-08-17
MX2015000397A (en) 2015-11-23
EA201590198A1 (en) 2015-06-30
AU2018203206A1 (en) 2018-05-24
AU2013290173A1 (en) 2015-01-22
KR102329315B1 (en) 2021-11-19
SI2882450T1 (en) 2020-02-28
PT2882450T (en) 2020-02-19
US10138291B2 (en) 2018-11-27
SG11201500045RA (en) 2015-02-27
ES2770501T3 (en) 2020-07-01
LT2882450T (en) 2020-03-25
US20220056108A1 (en) 2022-02-24
AU2013290173B2 (en) 2018-02-15
NZ703366A (en) 2018-03-23
KR102403545B1 (en) 2022-05-30
WO2014011819A3 (en) 2014-03-06
EP2882450A2 (en) 2015-06-17
TWI667258B (en) 2019-08-01
US20190169267A1 (en) 2019-06-06
PH12015500039A1 (en) 2015-03-16
HK1211228A1 (en) 2016-05-20
CY1122729T1 (en) 2021-03-12
SG10201913893XA (en) 2020-03-30
EA029685B1 (en) 2018-04-30
EA201792485A3 (en) 2019-03-29
AU2018203206B2 (en) 2020-08-06
AU2022252703A1 (en) 2022-11-10
AR091735A1 (en) 2015-02-25
CO7170123A2 (en) 2015-01-28

Similar Documents

Publication Publication Date Title
HK1211228A1 (en) Factor viii complex with xten and von willebrand factor protein, and uses thereof xten viii
HRP20190454T1 (en) Recombinant factor viii proteins
HK1208827A1 (en) Interleukin-2 fusion proteins and uses thereof -2
IL238192B (en) Antibodies recognizing alpha-synnuclein, compositions comprising same and uses thereof
IL233934B (en) Cd47 antibodies, compositions comprising the same and uses thereof
IL236348A0 (en) Anti-jagged antibodies, compositions comprising the same and uses thereof
HK1210790A1 (en) Modified factor polypeptides and uses thereof
EP2847223A4 (en) Anti-b7-h6 antibody, fusion proteins, and methods of using the same
EP2929045A4 (en) Protein expression enhancing polypeptides
EP2877854A4 (en) Fusion proteins and methods thereof
EP3077413A4 (en) Polypeptides, nucleic acids and uses thereof
EP2930189A4 (en) Chemokine-cytokine fusion protein and application thereof
EP2889307A4 (en) Alpha-conotoxin peptide, and medical composition and purpose thereof
EP2825548A4 (en) Modified kisspeptin peptides and uses thereof
EP3049153B8 (en) Cyclic amyloid-beta-binding peptides and the use thereof
SG10201507721SA (en) CHO-GMT Recombinant Protein Expression
EP2907822A4 (en) hnRNP A2* PROTEIN, NUCLEIC ACID FOR CODING PROTEIN AND USE THEREOF
EP3015548A4 (en) Novel polypeptide, and use thereof
EP3015549A4 (en) Novel polypeptide, and use thereof
EP3029071A4 (en) Saxatilin-fc fusion protein and use thereof
EP2873676A4 (en) Small molecular peptide and use thereof
GB201214974D0 (en) Avian proteins, nucleic acids and uses thereof
AU2012901619A0 (en) Fusion Proteins and Use Thereof